Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29885558 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL13464701 | 0.95 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL29529894 | 0.95 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL63091 | 0.95 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL29420869 | 0.95 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL18477111 | 0.95 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL13928604 | 0.95 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL30725384 | 0.95 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL18506201 | 0.95 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL20323949 | 0.92 | RIPK1 (0.31) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-113423430-B | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-118557747-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117337196-A | Pegylated antibody hydroxyl-containing drug conjugates | 深圳康源久远生物技术有限公司 | 2024-01-02 | — | — | CN | claimed |
| CN-115666642-A | Drug conjugates containing alpha-enolase antibodies and uses thereof | 上毅生物科技股份有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| EP-4687444-A1 | IMPROVED WAXY DELIVERY FORMS FOR OILY AGRONOMIC ACTIVE INGREDIENTS AND METHOD OF PREPARATION | CLEVER BIOSCIENCE S.R.L. (IT) | 2026-02-11 | — | — | EP | disclosed |
| EP-4674476-A1 | MAGNETIC FIELD VARIATION THERAPY FOR ENHANCING THERAPEUTIC AND DISINFECTION APPLICATIONS | Azyro SA (LU) | 2026-01-07 | — | — | EP | disclosed |
| EP-3802850-B1 | DEVICES AND SYSTEMS FOR GASTROINTESTINAL MICROBIOME DETECTION AND MANIPULATION | BT BIDCO INC (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4598583-A2 | AMIDE LINKAGES OF SUGAR MOIETIES TO AMINE TERMINATED LEASHES ATTACHED TO CARBOHYDRATE POLYMERS | Navidea Biopharmaceuticals, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4569003-A2 | CLAUDIN-6 ANTIBODIES AND CONJUGATES THEREOF AND USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-120153254-A | Methods for the treatment and diagnosis of bladder cancer | 基因泰克公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2022076364-A1 | COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS | AOA DX (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220071559-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | GLAS USA LLC | 2022-03-10 | — | — | US | disclosed |
| US-20220071894-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | BT BIDCO LLC | 2022-03-10 | — | — | US | disclosed |
| CN-114144169-A | Leuprolide acetate compositions and methods of using same for treating breast cancer | 托尔玛国际有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-114040778-A | Cell binding molecule-Tubulysin derivative conjugate and preparation method thereof | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3551293-B1 | RNASE FOR IMPROVED MICROBIAL DETECTION AND ANTIMICROBIAL SUSCEPTIBILITY TESTING | MICROBEDX INC (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071894-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | ACKR3, CXCR2, CXCR3 | RIPK1 1434/4885 |
| US-20220071559-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | TPMT, FABP2, SLC10A2 | RIPK1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.